Advances in Lymphoma Research:
Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It ca...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Boston, MA
Springer US
1996
|
| Schriftenreihe: | Cancer Treatment and Research
85 |
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results |
| Beschreibung: | 1 Online-Ressource (XI, 169 p) |
| ISBN: | 9781461541295 |
| DOI: | 10.1007/978-1-4615-4129-5 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046146148 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1996 |||| o||u| ||||||eng d | ||
| 020 | |a 9781461541295 |9 978-1-4615-4129-5 | ||
| 024 | 7 | |a 10.1007/978-1-4615-4129-5 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-4615-4129-5 | ||
| 035 | |a (OCoLC)1119103934 | ||
| 035 | |a (DE-599)BVBBV046146148 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 245 | 1 | 0 | |a Advances in Lymphoma Research |c edited by Fernando Cabanillas, M. Alma Rodriguez |
| 264 | 1 | |a Boston, MA |b Springer US |c 1996 | |
| 300 | |a 1 Online-Ressource (XI, 169 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Cancer Treatment and Research |v 85 | |
| 520 | |a Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Cancer Research | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Oncology | |
| 650 | 0 | 7 | |a Malignes Lymphom |0 (DE-588)4037233-9 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Malignes Lymphom |0 (DE-588)4037233-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Cabanillas, Fernando |4 edt | |
| 700 | 1 | |a Rodriguez, M. Alma |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461368519 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780792339298 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461541301 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4615-4129-5 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031526333 | ||
| 966 | e | |u https://doi.org/10.1007/978-1-4615-4129-5 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180483726114816 |
|---|---|
| any_adam_object | |
| author2 | Cabanillas, Fernando Rodriguez, M. Alma |
| author2_role | edt edt |
| author2_variant | f c fc m a r ma mar |
| author_facet | Cabanillas, Fernando Rodriguez, M. Alma |
| building | Verbundindex |
| bvnumber | BV046146148 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-4615-4129-5 (OCoLC)1119103934 (DE-599)BVBBV046146148 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-1-4615-4129-5 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03230nmm a2200505zcb4500</leader><controlfield tag="001">BV046146148</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1996 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781461541295</subfield><subfield code="9">978-1-4615-4129-5</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4615-4129-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-4615-4129-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119103934</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046146148</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Advances in Lymphoma Research</subfield><subfield code="c">edited by Fernando Cabanillas, M. Alma Rodriguez</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boston, MA</subfield><subfield code="b">Springer US</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XI, 169 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Cancer Treatment and Research</subfield><subfield code="v">85</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer Research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Malignes Lymphom</subfield><subfield code="0">(DE-588)4037233-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Malignes Lymphom</subfield><subfield code="0">(DE-588)4037233-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cabanillas, Fernando</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rodriguez, M. Alma</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461368519</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780792339298</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461541301</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4615-4129-5</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031526333</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4615-4129-5</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046146148 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:29Z |
| institution | BVB |
| isbn | 9781461541295 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031526333 |
| oclc_num | 1119103934 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XI, 169 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1996 |
| publishDateSearch | 1996 |
| publishDateSort | 1996 |
| publisher | Springer US |
| record_format | marc |
| series2 | Cancer Treatment and Research |
| spelling | Advances in Lymphoma Research edited by Fernando Cabanillas, M. Alma Rodriguez Boston, MA Springer US 1996 1 Online-Ressource (XI, 169 p) txt rdacontent c rdamedia cr rdacarrier Cancer Treatment and Research 85 Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results Oncology Cancer Research Oncology Malignes Lymphom (DE-588)4037233-9 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Malignes Lymphom (DE-588)4037233-9 s DE-604 Cabanillas, Fernando edt Rodriguez, M. Alma edt Erscheint auch als Druck-Ausgabe 9781461368519 Erscheint auch als Druck-Ausgabe 9780792339298 Erscheint auch als Druck-Ausgabe 9781461541301 https://doi.org/10.1007/978-1-4615-4129-5 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Advances in Lymphoma Research Oncology Cancer Research Oncology Malignes Lymphom (DE-588)4037233-9 gnd |
| subject_GND | (DE-588)4037233-9 (DE-588)4143413-4 |
| title | Advances in Lymphoma Research |
| title_auth | Advances in Lymphoma Research |
| title_exact_search | Advances in Lymphoma Research |
| title_full | Advances in Lymphoma Research edited by Fernando Cabanillas, M. Alma Rodriguez |
| title_fullStr | Advances in Lymphoma Research edited by Fernando Cabanillas, M. Alma Rodriguez |
| title_full_unstemmed | Advances in Lymphoma Research edited by Fernando Cabanillas, M. Alma Rodriguez |
| title_short | Advances in Lymphoma Research |
| title_sort | advances in lymphoma research |
| topic | Oncology Cancer Research Oncology Malignes Lymphom (DE-588)4037233-9 gnd |
| topic_facet | Oncology Cancer Research Oncology Malignes Lymphom Aufsatzsammlung |
| url | https://doi.org/10.1007/978-1-4615-4129-5 |
| work_keys_str_mv | AT cabanillasfernando advancesinlymphomaresearch AT rodriguezmalma advancesinlymphomaresearch |